Provided by Parkinson & Movement Disorder Alliance

Advanced Therapeutics in Movement & Related Disorders Congress® (ATMRD) is focused on reaching movement disorder specialists, neurologists, fellows, and advanced practice providers and aims to prepare learners to apply new knowledge, tools, and strategies to the diagnosis, treatment, and care of patients with movement disorders.  Learners will explore in-depth, science-based research focused on efficacy in real-world patients and engage in stimulating discussions of clinical practice case studies that use advanced therapeutics to solve treatment conundrums. 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 17.25 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Analyze the natural history of motor fluctuations in Parkinson’s disease and apply evidence-based strategies to manage motor complications, including optimizing medication regimens and selecting appropriate adjunctive therapies.
2. Recognize and assess common neuropsychiatric and non-motor features associated with movement and neurodegenerative disorders and select evidence-based approaches for their diagnosis and management.
3. Determine when advanced therapies should be considered and evaluate current evidence and clinical considerations for deep brain stimulation, infusion therapies, focused ultrasound, and other device-aided treatments.
4. Interpret biomarker and neurodiagnostic data to differentiate among neurodegenerative disorders and integrate this information to inform individualized patient care.
5. Differentiate among common hyperkinetic disorders based on clinical features and select evidence-based treatments appropriate to each condition.
6. Evaluate diagnostic and therapeutic strategies for Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease dementia, including the role of pathology-targeted and emerging disease-modifying therapies in clinical decision-making.
7. Apply evidence-based procedural principles to the safe and effective use of botulinum toxin and other interventional treatments, including patient selection, anatomical targeting, and technique-guided administration.

Faculty

Full list of faculty and panelists.  

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by independent medical education grants from Acadia, Merz, Supernus, Abbott, Boston Scientific, Ipsen, GE HealthCare. This activity is also supported with in-kind contributions and training supplies from Merz, Supernus, Ipsen, Revance, Ambu, and Cadwell.

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided via email, onsite, and through your conference app.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org